Travelling Prize Fellowships

Our Travelling Prize Fellowships aim to provide a unique opportunity for the most outstanding early career researchers to begin to develop their independent research careers, working in the best research environments in the UK and overseas. Applicants should demonstrate the potential to be an independent researcher, and these Fellowships will help to accelerate the career trajectories of successful recipients and ultimately ensure they make the biggest impact for men affected by prostate cancer.

These Fellowships provide the opportunity to spend at least six months at another research institution to establish collaborations as well as learning new skills and techniques that will support career development as a prostate cancer researcher.

• Awards are for three to four years. A period of at least six months must be spent outside of the Fellows' host institution (either elsewhere in the UK, or abroad). Awards can be for up to £250,000 if solely based in the UK, or a total of £300,000 if the Fellowship includes a placement at one or more institutions outside the UK.
• Applicants must be within 2 years of their PhD viva (reasonable career breaks will be taken into consideration). Candidates may also apply if they are in the final year of their PhD, but in this instance, they will be expected to have successfully passed their viva within the next 12 months.
• Travelling Prize Fellowships must be held at a UK-based University, NHS site or other recognised higher research institution.
• All awards made will be in line with our terms and conditions (please note - these terms may be subject to change). 
• All proposals must align with our research strategy.
• Further eligibility criteria will be detailed in the guidance notes once the call is open for applications.

You can view our current and previously funded Travelling Prize Fellowships by clicking on the links below.

• Dr Susan Heavey: SCREEN: utiliSation of Co-taRgeted thErapy in prostatE caNcer
• Dr Chris Armstrong: YKL40 signalling as a mechanism of relapse following radiotherapy in PTEN-deficient prostate cancer
• Dr James Grey: Ex vivo and in vivo validation of Myosin Phosphatase modulators as therapeutic targets in castrate resistant prostate cancer

If you have any questions or would like to discuss an application with the Research Team, please e-mail research@prostatecanceruk.org or call 020 3310 7258.